Skip to main content

Advertisement

SpringerLink
Log in

Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

A diagnosis of lobular carcinoma in situ (LCIS) is associated with an increased risk of developing breast cancer, although little data exist on long-term patient outcomes, including those who develop subsequent breast malignancies.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women with a histological diagnosis of LCIS between 1983 and 2014. The incidence and clinicopathologic features of subsequent malignancies were then examined, and the Kaplan–Meier method and multivariable Cox PH regression used to obtain breast cancer-specific survival (BCSS) estimates and associated hazard ratios.

Results

Overall, 19,462 women swith a mean age at LCIS diagnosis of 53.7 years, and a 10- and 20-year cumulative incidence of subsequent breast malignancy of 11.3% [95% confidence interval (CI) 10.7–11.9%] and 19.8% (95% CI 18.8–20.9) met the eligibility criteria. At a median follow-up of 8.1 years (range 0–30.9) a total of 1837 primary breast cancers were diagnosed, of which 55.2% were diagnosed in the ipsilateral breast. Most breast cancers were of low/intermediate grade, hormone receptor-positive, and diagnosed in early stages. Of subsequent malignancies, invasive ductal carcinoma (IDC) distributed equally across both breasts, whereas invasive lobular carcinoma (ILC) was more likely to present in the ipsilateral breast (69.0% ILC vs. 49.2% IDC; p < 0.001). On multivariable analysis, type of surgical treatment for LCIS had no affect on long-term survival (p = 0.44). The 10- and 20-year BCSS for women with LCIS was 98.9 and 96.3%, respectively.

Conclusion

Women with LCIS who are diagnosed with a subsequent primary breast cancer are often diagnosed in early stages and have excellent BCSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res. 2012;14:R103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bagaria SP, Shamonki J, Kinnaird M, Ray PS, Giuliano AE. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma? Ann Surg Oncol. 2011;18:1845–51.

    Article  PubMed  Google Scholar 

  3. Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, et al. Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Res. 2016;18:66.

    Article  PubMed  PubMed Central  Google Scholar 

  4. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404–11.

    Article  PubMed  Google Scholar 

  5. Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004;100:2562–72.

    Article  PubMed  Google Scholar 

  6. Vos CB, Cleton-Jansen AM, Berx G, De Leeuw WJ, Ter Haar NT, Van Roy F, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131–1133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106:2104–12.

    Article  PubMed  Google Scholar 

  8. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534–41.

    Article  PubMed  Google Scholar 

  9. King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33:3945–52.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.

    Article  CAS  PubMed  Google Scholar 

  12. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  13. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.

    Article  CAS  PubMed  Google Scholar 

  14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.

    Article  CAS  PubMed  Google Scholar 

  15. Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627–33.

    Article  CAS  PubMed  Google Scholar 

  16. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–95.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17:491–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.

    Article  CAS  PubMed  Google Scholar 

  19. Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P, Sinn HP, et al. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat. 2008;107:331–35.

    Article  PubMed  Google Scholar 

  20. Wheeler JE, Enterline HT, Roseman JM, Tomasulo JP, McIlvaine CH, Fitts WT, et al. Lobular carcinoma in situ of the breast. Long-term followup. Cancer. 1974;34:554–63.

    CAS  PubMed  Google Scholar 

  21. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238–44.

    Article  PubMed  Google Scholar 

  22. Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E, et al. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer. 2013;119:1073–79.

    Article  PubMed  Google Scholar 

  23. Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH. Lobular in situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012;19:914–21.

    Article  PubMed  Google Scholar 

  24. Shah-Khan MG, Geiger XJ, Reynolds C, Jakub JW, DePeri ER, Glazebrook KN. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19:3131–38.

    Article  PubMed  Google Scholar 

  25. Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, et al. Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020). Ann Surg Oncol. 2016;23:722–28.

    Article  PubMed  Google Scholar 

  26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology (NCCN Guidelines®. Breast cancer screening and diagnosis (BSCR-2). Version 1.2016. National Comprehensive Cancer Network; 2016.

  27. Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20:3240–46.

    Article  PubMed  Google Scholar 

  28. Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;5:546–53.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8–v30.

    Article  PubMed  Google Scholar 

  30. Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology. 2009;23:288–95.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, McGill University, Montreal, QC, Canada

    Stephanie M. Wong MD, MPH & Jean-Francois Boileau MD, MSc

  2. Department of Surgery, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, USA

    Tari King MD & Mehra Golshan MD

  3. Department of Surgery, Jewish General Segal Cancer Centre, Montreal, QC, Canada

    Jean-Francois Boileau MD, MSc

  4. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

    William T. Barry PhD

Authors
  1. Stephanie M. Wong MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tari King MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Francois Boileau MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William T. Barry PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehra Golshan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehra Golshan MD.

Ethics declarations

Disclosure

Stephanie M. Wong, Tari King, Jean-Francois Boileau, William T. Barry, and Mehra Golshan have no relevant conflicts of interest to disclose.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 11 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, S.M., King, T., Boileau, JF. et al. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann Surg Oncol 24, 2509–2517 (2017). https://doi.org/10.1245/s10434-017-5867-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5867-6

Keywords

Search

Navigation